Biomarkers of islet beta cell stress and death in type 1 diabetes

Emily K. Sims, Carmella Evans-Molina, Sarah A. Tersey, Decio L. Eizirik, Raghu Mirmira

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Recent work on the pathogenesis of type 1 diabetes has led to an evolving recognition of the heterogeneity of this disease, both with regards to clinical phenotype and responses to therapies to prevent or revert diabetes. This heterogeneity not only limits efforts to accurately predict clinical disease but also is reflected in differing responses to immunomodulatory therapeutics. Thus, there is a need for robust biomarkers of beta cell health, which could provide insight into pathophysiological differences in disease course, improve disease prediction, increase the understanding of therapeutic responses to immunomodulatory interventions and identify individuals most likely to benefit from these therapies. In this review, we outline current literature, limitations and future directions for promising circulating markers of beta cell stress and death in type 1 diabetes, including markers indicating abnormal prohormone processing, circulating RNAs and circulating DNAs.

Original languageEnglish (US)
JournalDiabetologia
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Type 1 Diabetes Mellitus
Islets of Langerhans
Cell Death
Biomarkers
Therapeutics
RNA
Phenotype
DNA
Health

Keywords

  • Biomarker
  • Diabetes mellitus
  • Pancreatic beta cells
  • Pancreatic islets
  • Review
  • Type 1 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Biomarkers of islet beta cell stress and death in type 1 diabetes. / Sims, Emily K.; Evans-Molina, Carmella; Tersey, Sarah A.; Eizirik, Decio L.; Mirmira, Raghu.

In: Diabetologia, 01.01.2018.

Research output: Contribution to journalArticle

@article{57c1cac3e14e4a02a8d4785b48911081,
title = "Biomarkers of islet beta cell stress and death in type 1 diabetes",
abstract = "Recent work on the pathogenesis of type 1 diabetes has led to an evolving recognition of the heterogeneity of this disease, both with regards to clinical phenotype and responses to therapies to prevent or revert diabetes. This heterogeneity not only limits efforts to accurately predict clinical disease but also is reflected in differing responses to immunomodulatory therapeutics. Thus, there is a need for robust biomarkers of beta cell health, which could provide insight into pathophysiological differences in disease course, improve disease prediction, increase the understanding of therapeutic responses to immunomodulatory interventions and identify individuals most likely to benefit from these therapies. In this review, we outline current literature, limitations and future directions for promising circulating markers of beta cell stress and death in type 1 diabetes, including markers indicating abnormal prohormone processing, circulating RNAs and circulating DNAs.",
keywords = "Biomarker, Diabetes mellitus, Pancreatic beta cells, Pancreatic islets, Review, Type 1 diabetes",
author = "Sims, {Emily K.} and Carmella Evans-Molina and Tersey, {Sarah A.} and Eizirik, {Decio L.} and Raghu Mirmira",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00125-018-4712-1",
language = "English (US)",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Biomarkers of islet beta cell stress and death in type 1 diabetes

AU - Sims, Emily K.

AU - Evans-Molina, Carmella

AU - Tersey, Sarah A.

AU - Eizirik, Decio L.

AU - Mirmira, Raghu

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Recent work on the pathogenesis of type 1 diabetes has led to an evolving recognition of the heterogeneity of this disease, both with regards to clinical phenotype and responses to therapies to prevent or revert diabetes. This heterogeneity not only limits efforts to accurately predict clinical disease but also is reflected in differing responses to immunomodulatory therapeutics. Thus, there is a need for robust biomarkers of beta cell health, which could provide insight into pathophysiological differences in disease course, improve disease prediction, increase the understanding of therapeutic responses to immunomodulatory interventions and identify individuals most likely to benefit from these therapies. In this review, we outline current literature, limitations and future directions for promising circulating markers of beta cell stress and death in type 1 diabetes, including markers indicating abnormal prohormone processing, circulating RNAs and circulating DNAs.

AB - Recent work on the pathogenesis of type 1 diabetes has led to an evolving recognition of the heterogeneity of this disease, both with regards to clinical phenotype and responses to therapies to prevent or revert diabetes. This heterogeneity not only limits efforts to accurately predict clinical disease but also is reflected in differing responses to immunomodulatory therapeutics. Thus, there is a need for robust biomarkers of beta cell health, which could provide insight into pathophysiological differences in disease course, improve disease prediction, increase the understanding of therapeutic responses to immunomodulatory interventions and identify individuals most likely to benefit from these therapies. In this review, we outline current literature, limitations and future directions for promising circulating markers of beta cell stress and death in type 1 diabetes, including markers indicating abnormal prohormone processing, circulating RNAs and circulating DNAs.

KW - Biomarker

KW - Diabetes mellitus

KW - Pancreatic beta cells

KW - Pancreatic islets

KW - Review

KW - Type 1 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85051635227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051635227&partnerID=8YFLogxK

U2 - 10.1007/s00125-018-4712-1

DO - 10.1007/s00125-018-4712-1

M3 - Article

C2 - 30112687

AN - SCOPUS:85051635227

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

ER -